scholarly journals Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression

2020 ◽  
Vol 26 (14) ◽  
pp. 3629-3640 ◽  
Author(s):  
Julian Marcon ◽  
Renzo G. DiNatale ◽  
Alejandro Sanchez ◽  
Ritesh R. Kotecha ◽  
Sounak Gupta ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Disease Progression ◽  
Renal Cell ◽  
Copy Number ◽  
Genomic Analysis ◽  
Copy Number Variations

scholarly journals Copy number variations and expression of MPDZ are prognostic biomarkers for clear cell renal cell carcinoma

Oncotarget ◽  
2017 ◽  
Vol 8 (45) ◽  
pp. 78713-78725 ◽  
Author(s):  
Yong-Sheng Huang ◽  
Wen-Bin Liu ◽  
Fei Han ◽  
Jun-Tang Yang ◽  
Xiang-Lin Hao ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Copy Number ◽  
Clear Cell ◽  
Copy Number Variations ◽  
Prognostic Biomarkers ◽  
Cell Renal Cell Carcinoma

scholarly journals Gankyrin is a novel biomarker for disease progression and prognosis of patients with renal cell carcinoma

EBioMedicine ◽  
2019 ◽  
Vol 39 ◽  
pp. 255-264 ◽  
Author(s):  
Chao Wang ◽  
Yan Li ◽  
Chuan-min Chu ◽  
Xiang-min Zhang ◽  
Jie Ma ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Disease Progression ◽  
Renal Cell

scholarly journals Genomic Analysis as the First Step toward Personalized Treatment in Renal Cell Carcinoma

2014 ◽  
Vol 4 ◽  
Author(s):  
Zofia Felicja Bielecka ◽  
Anna MaÅ‚gorzata Czarnecka ◽  
Cezary Szczylik
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Genomic Analysis ◽  
Personalized Treatment

Comparison of First-line Pazopanib and Sunitinib in Metastatic Renal Cell Carcinoma: Experiences of the Urologic Cancer Centre for Research and Innovation

2019 ◽  
Author(s):  
Emily C.L. Wong ◽  
Camilla Tajzler ◽  
Gaurav Vasisth ◽  
Amanda Zhu ◽  
Mathilda Chow ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Side Effects ◽  
Cell Carcinoma ◽  
Disease Progression ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy ◽  
Significant Difference

Abstract Background: Sunitinib and pazopanib are orally-administered tyrosine kinase receptor inhibitors (TKIs) approved as first-line therapy for the treatment of metastatic renal cell carcinoma (mRCC). The IMDC criteria are a predictive prognostic model for patients with mRCC when stratified into three prognosis groups: favourable, intermediate and poor. We retrospectively compared the efficacy and safety of sunitinib and pazopanib as first-line therapy for patients with mRCC in our single institution database. Methods: Retrospective analysis was done to compare progression-free survival (PFS) and side effects of sunitinib and pazopanib as first-line therapy in patients with mRCC. Patients were stratified into prognosis groups according to IMDC criteria. Disease assessment was performed on measurable aspects of disease based on computed tomography or magnetic resonance imaging reports. Survival analysis was performed using the Kaplan-Meier method and Cox regression, with disease progression as the endpoint.Results: Data was obtained from 228 patients with mRCC who were treated with either pazopanib (n=57) or sunitinib (n=171). No significant difference in PFS was found between sunitinib and pazopanib (HR for disease progression or all-cause death, 1.10; 95%CI: 0.76-1.57, p=0.62). Median PFS time for patients receiving sunitinib was 9.4 months and for pazopanib, 8.5 months. Median PFS for patients with intermediate-risk disease was similar between groups (9.4 months vs. 9.2 months, respectively, p=0.93). However, patients treated with sunitinib experienced a greater number of side effects compared to pazopanib. Conclusions: Sunitinib and pazopanib are similarly efficacious as first-line therapy for mRCC. However, adverse events are lower with pazopanib.

scholarly journals Dose escalation of axitinib on disease progression as a strategy in the treatment of metastatic renal cell carcinoma

ESMO Open ◽  
2018 ◽  
Vol 3 (7) ◽  
pp. e000445 ◽  
Author(s):  
Gary Joseph Doherty ◽  
Deirdre Lynskey ◽  
Athena Matakidou ◽  
Kate Fife ◽  
Tim Eisen
Keyword(s):  
Renal Cell Carcinoma ◽  
Disease Control ◽  
Cell Carcinoma ◽  
Disease Progression ◽  
Metastatic Renal Cell Carcinoma ◽  
Dose Escalation ◽  
Renal Cell ◽  
Kinase Inhibitor ◽  
Drug Label ◽  
Entire Cohort

IntroductionThe AXIS trial established axitinib as a standard of care treatment for patients with metastatic renal cell carcinoma (mRCC) after failure of a prior tyrosine kinase inhibitor. Axitinib dosing begins at 5  mg twice daily, with escalation of doses to 7  and 10  mg after consecutive 2-week intervals if tolerated (as per the drug label). Given clinical concerns about drug-related toxicity, we have used a pragmatic strategy where dose escalations were made only after disease progression or where rapid responses were clinically required.MethodsWe performed a retrospective review of electronic health records and radiology of all patients with mRCC treated with axitinib for >2 weeks at Addenbrooke’s Hospital, Cambridge, UK, over a 37 -month period to determine the clinical and radiological effects of dose escalations made according to the above strategy.Results42 patients fitting these criteria were identified, 29 having ≥1  dose escalation event (DEE). 60 DEEs were identified (median of two per patient), and the objective radiological consequences of 53 DEEs could be evaluated. The disease control rate (partial response or stable disease) after the first DEE instituted for disease progression was similar to that after the second DEE (68.8% vs 70%). 56.6 % of all DEEs and 63.6 % of DEEs made as a result of disease progression resulted in disease control. The median OS from the commencement of axitinib for all dose-escalated patients was 19.9 months, and 16.5 months for the entire cohort. The mean dose (for all patients) at 90 days after starting axitinib was 5.92  mg.ConclusionThese data suggest that dose escalation of axitinib after disease progression may be an effective dosing strategy for patients with mRCC, and this may be a preferred option in patients in whom there are particular concerns about drug-related toxicity, quality of life optimisation or healthcare-associated costs.

scholarly journals VEGFA amplification/increased gene copy number and VEGFA mRNA expression in renal cell carcinoma with TFEB gene alterations

2018 ◽  
Vol 32 (2) ◽  
pp. 258-268 ◽  
Author(s):  
Anna Caliò ◽  
Matteo Brunelli ◽  
Diego Segala ◽  
Serena Pedron ◽  
Claudio Doglioni ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Mrna Expression ◽  
Renal Cell ◽  
Copy Number ◽  
Gene Copy Number ◽  
Gene Copy ◽  
Gene Alterations
Sign in / Sign up

Export Citation Format

Share Document